Abstract：Objective：To observe the clinical efficacy of Jinfukang Oral Liquid combined with Camrelizumab on non-small cell lung cancer （NSCLC）， and to evaluate it using the patient-reported outcomes （PRO）. Methods： A total of 80 NSCLC patients admitted to the First People's Hospital of Shangqiu from April 2024 to April 2025 were selected and divided into the combination group and the monoclonal antibody group according to the random number table method， with 40 cases in each group. The monoclonal antibody group was treated with Camrelizumab， and the combination group was treated with Jinfukang Oral Liquid combined with Camrelizumab. The efficacy and incidence of adverse reactions， and before and after treatment， the traditional Chinese medicine syndrome score， PRO indexes [scores of Quality of Life Questionnaire Core-30（ QLQ-C30） for lung cancer]，levels of tumor markers [carcinoembryonic antigen （CEA）， tumor specific growth factor （TSGF）， cytokeratin 19 fragment antigen （CYFRA21-1）]， levels of immune indexes （CD4+ ， CD4+/CD8+） were compared between the two groups. Results： After treatment， the total effective rate was 82.50% （33/40） in the combination group， higher than that of 62.50% （25/40） in the monoclonal antibody group， the difference being significant （P＜0.05）. After treatment， the traditional Chinese medicine syndrome scores of chest distress，cough，weakness，shortness of breath and reluctance to talk，spontaneous sweating and night sweating， and dry mouth and pharynx in both groups were decreased when compared with those before treatment （P＜0.05），and the above scores in the combination group were lower than those in the monoclonal antibody group （P＜0.05）. After treatment， the scores of three domains in QLQ-C30 for lung cancer in the two groups were reduced when compared with those before treatment （P＜0.05）， and the above scores in the combination group were lower than those in the monoclonal antibody group （P＜0.05）. After treatment，the levels of CYFRA21-1，TSGF，and CEA in both groups were decreased when compared with those before treatment （P＜0.05），and the above levels in the combination group were lower than those in the monoclonal antibody group （P＜0.05）. After treatment， the levels of CD4+ and CD4+/CD8+ in the two groups were increased when compared with those before treatment （P＜0.05），and the above levels in the combination group were higher than those in the monoclonal antibody group （P＜0.05）. During treatment，the incidence of adverse reactions was 17.50% （7/40） in the combination group，and 40.00% （16/40） in the monoclonal antibody group， the difference being significant （P＜0.05）. Conclusion： The combined use of Jinfukang Oral Liquid and Camrelizumab has a definite curative effect on NSCLC， especially in improving patients' emotions and symptoms. It can also enhance the immune function and quality of life with higher safety.